US Bancorp
BOLD

US Bancorp’s Audentes Therapeutics, Inc BOLD Stock Holding History

US Bancorp’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-6
Closed – – 3715
2018
Q4 		$0 Hold
6
– – ﹤0.01% 3768
2018
Q3 		$0 Hold
6
– – ﹤0.01% 3747
2018
Q2 		$0 Hold
6
– – ﹤0.01% 3747
2018
Q1 		$0 Hold
6
– – ﹤0.01% 3750
2017
Q4 		$0 Hold
6
– – ﹤0.01% 3729
2017
Q3 		$0 Hold
6
– – ﹤0.01% 3689
2017
Q2 		$0 Buy
+6
New +$96 ﹤0.01% 3660

Other funds holding BOLD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

US Bancorp's BOLD Position: Q1 2019 in Review

US Bancorp sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2019, closing a stake of 6 shares.

US Bancorp first reported a position in BOLD in Q2 2017 and held it in 7 quarters. The position peaked at $0 in Q4 2018. 139 funds tracked by Wall St. Rank hold BOLD as of Q1 2019.

  • US Bancorp reported no remaining Audentes Therapeutics, Inc position as of Q1 2019 after selling out during the quarter.
  • US Bancorp sold 6 Audentes Therapeutics, Inc shares in Q1 2019.
  • US Bancorp first reported a position in Audentes Therapeutics, Inc in Q2 2017 and held it in 7 quarters.
  • US Bancorp's Audentes Therapeutics, Inc position peaked at $0 in Q4 2018.
  • 139 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2019.

Based on US Bancorp's 13F filing for Q1 2019, filed 8 May 2019.